Pharmacokinetics of asundexian with combined CYP3A and P‐gp inhibitors and an inducer: Target in vitro and in vivo studies

Documenti analoghi

• Prescriptions of CYP3A4‐ and P‐gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention
  di: Stephanie C. M. Wuyts, et al.
  Pubblicazione: (2025)
• No Influence of Asundexian on Cardiac Repolarization
  di: Christine Brase, et al.
  Pubblicazione: (2024)
• Pharmacokinetics of betamethasone in pre‐eclampsia: An in vivo and ex vivo study
  di: Sam Schoenmakers, et al.
  Pubblicazione: (2025)
• Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
  di: Huijun Chen, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants
  di: Mohammad Ghasemi, et al.
  Pubblicazione: (2025)